Jixuan (Jessie) completed her PhD in 2018 at UNSW. She joined CMRI in 2021, where she is investigating the potential of modulating the Alternative Lengthening of Telomeres (ALT) pathway as a form of cancer therapy. 

She is currently studying therapeutic opportunities to target ALT cancers.